3/22/2012

U.S. biotech startup Inserogen has transformed tobacco plants into biological factories for manufacturing proteins for new vaccines and treatments. Using the SwiftVax tobacco plants, the startup is developing a vaccine for Newcastle disease, and a therapeutic protein for patients with alpha-1 antitrypsin deficiency. "The technology is easy to customize, and can be engineered to produce not only vaccines, but virtually any recombinant protein," Inserogen's Lucas Arzola said.

Related Summaries